Kodiak Sciences Stock Is Surging Friday: What's Driving The Action?

Kodiak Sciences Inc (NASDAQ: KOD) shares surged 13.68% to $45.20, reaching a new 52-week high after the company announced positive topline results from its Phase 3 GLOW2 study for Zenkuda in diabetic retinopathy. The study showed that 62.5% of treated patients achieved significant improvements in Diabetic Retinopathy Severity Scale scores, and Zenkuda reduced the risk of sight-threatening complications by 85%. Kodiak plans to accelerate the submission timeline for a biologics license application, highlighting the drug's favorable safety profile.